| |
NYS DURB HCV Mtg Feb 26
|
| |
| |
Download the PDF here
Medicaid Drug Utilization Review Board
Meeting Agenda for February 26, 2015
The Drug Utilization Review (DUR) Board will meet on
February 26, 2015 from 9:00 a.m. to 4:00 p.m.
Meeting Room 6, Concourse,
Empire State Plaza, Albany, New York
http://www.health.ny.gov/health_care/medicaid/program/dur/meetings/2015/index.htm
Hepatitis C Virus - Recently Approved Therapies
(ombitasvir/paritaprevir/ritonavir with dasabuvir - Viekira)
The Hepatitis C Virus agenda item will also include a Preferred Drug Program
(PDP) review of new clinical and financial information for the Hepatitis C -
Direct Acting Antiviral therapeutic class (PDP class listed below). The Board
will review new clinical and financial information and recommend preferred or
non-preferred status for products within the therapeutic class.
Hepatitis C - Direct Acting Antivirals
Copegus (ribavirin), Harvoni (ledipasvir/sofosbuvir), Moderiba (ribavirin),
Olysio (simeprevir), Rebetol (ribavirin), Ribapak (ribavirin), Ribasphere
(ribavirin), ribavirin, Sovaldi (sofosbuvir), Victrelis (boceprevir), Viekira
(ombitasvir/paritaprevir/ritonavir with dasabuvir)
The current preferred or non-preferred status of products in the Hepatitis C -
Direct Acting Antiviral therapeutic class may be viewed at:
https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf
|
|
| |
| |
|
|
|
